Jazz Pharmaceuticals Stock Price, News & Analysis (NASDAQ:JAZZ)

$145.76 +1.77 (+1.23 %)
(As of 02/20/2018 10:24 AM ET)
Previous Close$145.76
Today's Range$143.28 - $146.32
52-Week Range$128.58 - $163.75
Volume294,700 shs
Average Volume428,127 shs
Market Capitalization$8.74 billion
P/E Ratio24.01
Dividend YieldN/A
Beta0.99

About Jazz Pharmaceuticals (NASDAQ:JAZZ)

Jazz Pharmaceuticals logoJazz Pharmaceuticals, Inc. is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder. Its marketed products and late-stage product candidate are Xyrem (sodium oxybate) oral solution, Luvox CR (fluvoxamine maleate) Extended-Release Capsules and JZP-6 (sodium oxybate). Its other product candidates in clinical development are oral tablet forms of sodium oxybate; JZP-8 (intranasal clonazepam); JZP-4 (elpetrigine), and JZP-7 (ropinirole gel).

Receive JAZZ News and Ratings via Email

Sign-up to receive the latest news and ratings for JAZZ and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:JAZZ
CUSIPG5087110
Phone353-1634-7800

Debt

Debt-to-Equity Ratio0.63%
Current Ratio3.10%
Quick Ratio2.94%

Price-To-Earnings

Trailing P/E Ratio24.0132191321567
Forward P/E Ratio14.93
P/E Growth0.77

Sales & Book Value

Annual Sales$1.49 billion
Price / Sales5.87
Cash Flow$8.89 per share
Price / Cash16.39
Book Value$31.34 per share
Price / Book4.65

Profitability

Trailing EPS$6.07
Net Income$396.83 million
Net Margins23.58%
Return on Equity22.92%
Return on Assets10.07%

Miscellaneous

Employees1,040
Outstanding Shares59,950,000

Jazz Pharmaceuticals (NASDAQ:JAZZ) Frequently Asked Questions

What is Jazz Pharmaceuticals' stock symbol?

Jazz Pharmaceuticals trades on the NASDAQ under the ticker symbol "JAZZ."

How were Jazz Pharmaceuticals' earnings last quarter?

Jazz Pharmaceuticals plc - (NASDAQ:JAZZ) issued its quarterly earnings data on Tuesday, August, 9th. The specialty pharmaceutical company reported $2.63 earnings per share for the quarter, missing the Zacks' consensus estimate of $2.80 by $0.17. The specialty pharmaceutical company earned $381 million during the quarter, compared to the consensus estimate of $376.40 million. Jazz Pharmaceuticals had a return on equity of 22.92% and a net margin of 23.58%. Jazz Pharmaceuticals's quarterly revenue was up 14.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.41 earnings per share. View Jazz Pharmaceuticals' Earnings History.

When will Jazz Pharmaceuticals make its next earnings announcement?

Jazz Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, February, 27th 2018. View Earnings Estimates for Jazz Pharmaceuticals.

Where is Jazz Pharmaceuticals' stock going? Where will Jazz Pharmaceuticals' stock price be in 2018?

19 analysts have issued twelve-month price objectives for Jazz Pharmaceuticals' stock. Their forecasts range from $150.00 to $206.00. On average, they anticipate Jazz Pharmaceuticals' stock price to reach $180.00 in the next twelve months. View Analyst Ratings for Jazz Pharmaceuticals.

What are Wall Street analysts saying about Jazz Pharmaceuticals stock?

Here are some recent quotes from research analysts about Jazz Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Jazz lowered its earnings guidance for 2017, mainly due to lower-than-expected sales from Xyrem. Xyrem is facing patent challenges in the United States. Jazz has also been facing difficulties in building sufficient inventory levels for leukemia drug, Erwinaze, due to constrained manufacturing capacity. The company has its share of pipeline setback too. However, its lead pipeline candidate, JZP-110, currently evaluated for treatment of EDS, complements its existing sleep disorder portfolio. Nonetheless, the FDA approval of, Vyxeos in August, lends huge boost to the company, given its huge commercial potential in the target market. Shares of the company outperformed the industry in the last one year." (1/12/2018)
  • 2. Cantor Fitzgerald analysts commented, "Cantor Fitzgerald will host a physician conference call on Tuesday to provide perspective on pitolisant as it relates to JAZZ’s sleep franchise. The call is at 1:00pm EST and the dial in number can be obtained from your Cantor sales rep. Note that the call will be 30 minutes in duration. Questions for the consultant can be emailed to [email protected]" (12/3/2017)
  • 3. Mizuho analysts commented, "We raise our PT to $162 from $152 while reiterating our Buy rating following positive Phase III data in a key pipeline drug (JZP-110) in obstructive sleep apnea. Our PT went up due to increased likelihood of FDA approval." (3/21/2017)
  • 4. Cowen Inc analysts commented, "complete re-rating."Cacciatore comments, "We continue to believe Jazz is nearing a very interesting inflection point, as a favorable resolution to the Xyrem litigation is likely, which could extend the franchise to 2024/2025. Combined with JZP-110's potential $750MM+ opportunity to complement growing Defitelio, Erwinaze, and ultimately Vyxeos, we believe a complete re-rating is nearing. We would add here." (3/20/2017)

Who are some of Jazz Pharmaceuticals' key competitors?

Who owns Jazz Pharmaceuticals stock?

Jazz Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (4.69%), Bank of New York Mellon Corp (2.94%), Renaissance Technologies LLC (2.08%), Boston Partners (2.00%), TIAA CREF Investment Management LLC (1.64%) and Viking Global Investors LP (1.50%). Company insiders that own Jazz Pharmaceuticals stock include Bruce C Cozadd, Heather Ann Mcsharry, Iain Mcgill, Karen J Wilson, Karen L Smith, Kenneth W O'keefe, Matthew P Young, Michael Patrick Miller, Patrick G Enright, Paul L Berns, Paul Treacy, Rick E Winningham, Russell J Cox, Seamus Mulligan and Suzanne Sawochka Hooper. View Institutional Ownership Trends for Jazz Pharmaceuticals.

Who sold Jazz Pharmaceuticals stock? Who is selling Jazz Pharmaceuticals stock?

Jazz Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Viking Global Investors LP, Amundi Pioneer Asset Management Inc., Tekla Capital Management LLC, American Century Companies Inc., Millennium Management LLC, Schroder Investment Management Group, KBC Group NV and TIAA CREF Investment Management LLC. Company insiders that have sold Jazz Pharmaceuticals company stock in the last year include Bruce C Cozadd, Iain Mcgill, Karen J Wilson, Matthew P Young, Michael Patrick Miller, Patrick G Enright, Paul L Berns, Paul Treacy, Rick E Winningham and Suzanne Sawochka Hooper. View Insider Buying and Selling for Jazz Pharmaceuticals.

Who bought Jazz Pharmaceuticals stock? Who is buying Jazz Pharmaceuticals stock?

Jazz Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Boston Partners, Compagnie Lombard Odier SCmA, Bank of New York Mellon Corp, Goldman Sachs Group Inc., Two Sigma Investments LP, Two Sigma Advisers LP, Teachers Advisors LLC and APG Asset Management N.V.. Company insiders that have bought Jazz Pharmaceuticals stock in the last two years include Karen L Smith and Kenneth W O'keefe. View Insider Buying and Selling for Jazz Pharmaceuticals.

How do I buy Jazz Pharmaceuticals stock?

Shares of Jazz Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Jazz Pharmaceuticals' stock price today?

One share of Jazz Pharmaceuticals stock can currently be purchased for approximately $145.76.

How big of a company is Jazz Pharmaceuticals?

Jazz Pharmaceuticals has a market capitalization of $8.74 billion and generates $1.49 billion in revenue each year. The specialty pharmaceutical company earns $396.83 million in net income (profit) each year or $6.07 on an earnings per share basis. Jazz Pharmaceuticals employs 1,040 workers across the globe.

How can I contact Jazz Pharmaceuticals?

Jazz Pharmaceuticals' mailing address is FIFTH FLOOR WATERLOO EXCHANGE WATERLOO ROAD, DUBLIN L2, D04. The specialty pharmaceutical company can be reached via phone at 353-1634-7800 or via email at [email protected]


MarketBeat Community Rating for Jazz Pharmaceuticals (JAZZ)

Community Ranking:  3.8 out of 5 (star star star)
Outperform Votes:  730 (Vote Outperform)
Underperform Votes:  238 (Vote Underperform)
Total Votes:  968
MarketBeat's community ratings are surveys of what our community members think about Jazz Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Jazz Pharmaceuticals (NASDAQ:JAZZ) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.742.752.762.89
Ratings Breakdown: 0 Sell Rating(s)
5 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
15 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
16 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
16 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $180.00$181.00$181.71$185.00
Price Target Upside: 19.85% upside20.51% upside34.29% upside29.72% upside

Jazz Pharmaceuticals (NASDAQ:JAZZ) Consensus Price Target History

Price Target History for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Jazz Pharmaceuticals (NASDAQ:JAZZ) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/16/2018B. RileyReiterated RatingBuy$206.00LowView Rating Details
1/16/2018Deutsche BankSet Price TargetBuy$170.00MediumView Rating Details
1/2/2018Leerink SwannInitiated CoverageOutperform -> Outperform$180.00LowView Rating Details
12/25/2017Wells Fargo & CoReiterated RatingBuyLowView Rating Details
12/10/2017Cantor FitzgeraldReiterated RatingBuy$200.00LowView Rating Details
12/5/2017MizuhoBoost Price TargetNeutral -> Neutral$144.00 -> $150.00LowView Rating Details
11/10/2017HC WainwrightReiterated RatingNeutral -> Neutral$144.00 -> $150.00N/AView Rating Details
11/8/2017Royal Bank of CanadaLower Price TargetOutperform$210.00 -> $195.00N/AView Rating Details
10/26/2017Stifel NicolausReiterated RatingBuy$190.00N/AView Rating Details
10/23/2017CowenSet Price TargetBuy$190.00N/AView Rating Details
10/21/2017Piper Jaffray CompaniesSet Price TargetBuy$177.00N/AView Rating Details
10/19/2017FBR & CoInitiated CoverageBuy -> Buy$206.00N/AView Rating Details
10/5/2017Morgan StanleyInitiated CoverageEqual -> Equal Weight$155.00N/AView Rating Details
9/28/2017Goldman Sachs GroupInitiated CoverageNeutral -> Neutral$165.00LowView Rating Details
9/20/2017BMO Capital MarketsReiterated RatingBuy$196.00HighView Rating Details
9/18/2017JPMorgan Chase & Co.Reiterated RatingBuy$190.00LowView Rating Details
8/9/2017Janney Montgomery ScottReiterated RatingBuy$180.00 -> $192.00LowView Rating Details
5/22/2017Sanford C. BernsteinSet Price TargetMarket Perform$160.00 -> $176.00LowView Rating Details
2/22/2017Evercore ISIInitiated CoverageBuy$160.00N/AView Rating Details
2/16/2017GuggenheimReiterated RatingBuyN/AView Rating Details
1/19/2017SunTrust BanksReiterated RatingBuy$210.00N/AView Rating Details
1/18/2017BarclaysReiterated RatingOverweight$200.00N/AView Rating Details
4/5/2016Canaccord GenuityReiterated RatingBuy$170.00N/AView Rating Details
4/1/2016Northland SecuritiesReiterated RatingOutperform$175.00N/AView Rating Details
(Data available from 2/20/2016 forward)

Earnings

Jazz Pharmaceuticals (NASDAQ:JAZZ) Earnings History and Estimates Chart

Earnings by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Jazz Pharmaceuticals (NASDAQ JAZZ) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/27/2018$2.98N/AView Earnings Details
11/7/2017Q3 2017$2.53$2.93$420.67 million$411.86 millionViewN/AView Earnings Details
8/8/20176/30/2017$1.85$1.72$410.83 million$394.39 millionViewListenView Earnings Details
5/9/20173/31/2017$1.42$1.41$376.58 million$376.10 millionViewListenView Earnings Details
2/28/2017Q416$2.65$1.91$398.91 million$396.62 millionViewListenView Earnings Details
11/8/2016Q316$2.61$2.16$389.34 million$374.00 millionViewListenView Earnings Details
8/9/2016Q216$2.80$2.63$376.40 million$381.00 millionViewN/AView Earnings Details
5/10/2016Q1$2.31$2.26$338.86 million$336.00 millionViewListenView Earnings Details
2/23/2016Q415$2.60$2.60$349.98 million$340.90 millionViewListenView Earnings Details
11/9/2015Q315$2.56$2.52$348.15 million$340.90 millionViewListenView Earnings Details
8/5/2015Q215$2.41$2.41$335.58 million$333.70 millionViewListenView Earnings Details
5/7/2015Q115$2.15$1.99$309.50 million$309.30 millionViewListenView Earnings Details
2/24/2015Q414$2.30$2.44$319.74 million$328.10 millionViewListenView Earnings Details
11/4/2014Q314$1.98$2.33$302.90 million$306.58 millionViewListenView Earnings Details
8/5/2014Q214$1.92$2.05$273.39 million$291.23 millionViewListenView Earnings Details
5/8/2014Q114$1.79$1.61$254.86 million$247.00 millionViewListenView Earnings Details
2/25/2014Q413$1.78$1.72$238.12 million$235.80 millionViewListenView Earnings Details
11/5/2013Q313$1.67$1.78$227.38 million$232.20 millionViewListenView Earnings Details
8/6/2013Q2 2013$1.52$1.43$208.71 million$208.30 millionViewListenView Earnings Details
5/7/2013Q1 2013$1.35$1.37$189.92 million$196.20 millionViewListenView Earnings Details
2/26/2013Q4 2012$1.41$1.53$183.80 million$183.70 millionViewListenView Earnings Details
11/8/2012Q312$1.31$1.29$178.57 million$175.50 millionViewN/AView Earnings Details
8/7/2012$1.05$1.09ViewN/AView Earnings Details
5/8/2012$0.90$0.91ViewN/AView Earnings Details
2/27/2012Q4 2011$1.01$0.96ViewN/AView Earnings Details
11/1/2011$0.89$0.94ViewN/AView Earnings Details
7/28/2011$0.67$0.82ViewN/AView Earnings Details
5/3/2011$0.57$0.59ViewN/AView Earnings Details
3/7/2011$0.60$0.63ViewN/AView Earnings Details
11/4/2010Q3 2010$0.29$0.32ViewN/AView Earnings Details
8/10/2010Q2 2010$0.14$0.17ViewN/AView Earnings Details
5/5/2010Q1 2010$0.14$0.12ViewN/AView Earnings Details
3/3/2010Q4 2009$0.05$0.17ViewN/AView Earnings Details
11/5/2009Q3 2009($0.14)($0.05)ViewN/AView Earnings Details
8/11/2009Q2 2009($0.33)$0.08ViewN/AView Earnings Details
5/7/2009Q1 2009($0.45)ViewN/AView Earnings Details
3/26/2009Q4 2008($1.08)($0.97)ViewN/AView Earnings Details
11/13/2008Q3 2008($1.25)($1.07)ViewN/AView Earnings Details
8/7/2008Q2 2008($1.74)($2.18)ViewN/AView Earnings Details
5/13/2008Q1 2008($1.65)($1.97)ViewN/AView Earnings Details
2/13/2008Q4 2007($1.87)($1.64)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Jazz Pharmaceuticals (NASDAQ:JAZZ) Earnings Estimates

Current Year EPS Consensus Estimate: $9.76 EPS
Next Year EPS Consensus Estimate: $11.67 EPS

Dividends

Dividend History for Jazz Pharmaceuticals (NASDAQ:JAZZ)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Jazz Pharmaceuticals (NASDAQ JAZZ) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.30%
Institutional Ownership Percentage: 89.28%
Insider Trades by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)
Insider Trades by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Jazz Pharmaceuticals (NASDAQ JAZZ) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/14/2018Michael Patrick MillerEVPSell200$139.99$27,998.0021,469View SEC Filing  
1/16/2018Matthew P. YoungCFOSell700$152.16$106,512.00View SEC Filing  
1/12/2018Bruce C. CozaddCEOSell3,000$150.00$450,000.00View SEC Filing  
1/12/2018Michael Patrick MillerEVPSell200$148.65$29,730.0021,669View SEC Filing  
12/11/2017Michael Patrick MillerEVPSell200$139.15$27,830.00View SEC Filing  
12/11/2017Patrick G. EnrightDirectorSell9,000$139.73$1,257,570.00View SEC Filing  
11/17/2017Iain McgillSVPSell8,000$133.42$1,067,360.0028,383View SEC Filing  
11/17/2017Patrick G EnrightDirectorSell352$133.19$46,882.881,365View SEC Filing  
10/2/2017Bruce C CozaddCEOSell1,000$150.00$150,000.00View SEC Filing  
9/12/2017Bruce C. CozaddCEOSell1,000$153.52$153,520.00View SEC Filing  
8/25/2017Patrick G EnrightDirectorSell351$148.40$52,088.401,717View SEC Filing  
8/15/2017Michael Patrick MillerEVPSell200$144.38$28,876.0021,996View SEC Filing  
8/14/2017Paul TreacySVPSell1,304$143.32$186,889.28View SEC Filing  
8/11/2017Paul L BernsDirectorSell662$142.37$94,248.946,599View SEC Filing  
7/20/2017Suzanne Sawochka HooperEVPSell4,580$160.00$732,800.0032,322View SEC Filing  
7/17/2017Michael Patrick MillerEVPSell200$154.97$30,994.00View SEC Filing  
6/23/2017Suzanne Sawochka HooperEVPSell420$160.00$67,200.00View SEC Filing  
6/15/2017Michael Patrick MillerEVPSell200$150.65$30,130.0022,223View SEC Filing  
6/1/2017Rick E WinninghamDirectorSell5,000$150.00$750,000.0010,391View SEC Filing  
5/15/2017Michael Patrick MillerEVPSell200$152.98$30,596.0022,623View SEC Filing  
5/11/2017Bruce C CozaddCEOSell30,000$153.47$4,604,100.00296,418View SEC Filing  
5/9/2017Suzanne Sawochka HooperEVPSell2,500$160.00$400,000.0037,149View SEC Filing  
4/27/2017Karen J WilsonSVPSell1,275$160.00$204,000.0021,133View SEC Filing  
4/27/2017Suzanne Sawochka HooperEVPSell2,500$160.00$400,000.0039,649View SEC Filing  
4/17/2017Michael Patrick MillerSVPSell200$152.56$30,512.0022,562View SEC Filing  
4/11/2017Bruce C CozaddCEOSell1,000$152.12$152,120.00308,491View SEC Filing  
4/10/2017Karen J WilsonSVPSell11,458$152.24$1,744,365.9227,158View SEC Filing  
3/15/2017Michael Patrick MillerSVPSell200$137.89$27,578.0022,762View SEC Filing  
3/6/2017Paul TreacySVPSell884$131.97$116,661.4818,108View SEC Filing  
2/15/2017Michael Patrick MillerSVPSell200$134.55$26,910.0016,486View SEC Filing  
1/18/2017Russell J. CoxCOOSell4,000$128.75$515,000.00View SEC Filing  
1/17/2017Michael Patrick MillerSVPSell200$115.93$23,186.0016,686View SEC Filing  
12/15/2016Michael Patrick MillerSVPSell200$103.09$20,618.00View SEC Filing  
12/2/2016Patrick G EnrightDirectorSell677$101.80$68,918.601,365View SEC Filing  
11/15/2016Michael Patrick MillerSVPSell200$112.19$22,438.0016,925View SEC Filing  
11/14/2016Kenneth W O'keefeDirectorBuy2,000$113.84$227,680.0012,107View SEC Filing  
10/17/2016Michael Patrick MillerSVPSell200$118.16$23,632.0017,125View SEC Filing  
9/19/2016Michael Patrick MillerSVPSell200$126.17$25,234.0017,325View SEC Filing  
8/25/2016Seamus MulliganDirectorSell27,968$128.32$3,588,853.761,072,411View SEC Filing  
8/16/2016Paul TreacySVPSell1,292$137.47$177,611.24View SEC Filing  
8/15/2016Michael Patrick MillerSVPSell100$136.45$13,645.0017,525View SEC Filing  
8/15/2016Rick E WinninghamDirectorSell633$136.45$86,372.8515,391View SEC Filing  
8/12/2016Karen L SmithInsiderBuy608$137.10$83,356.8014,181View SEC Filing  
8/9/2016Bruce C. CozaddCEOSell1,000$150.00$150,000.00View SEC Filing  
8/9/2016Russell J. CoxCOOSell4,000$148.66$594,640.00View SEC Filing  
7/15/2016Michael Patrick MillerSVPSell100$142.43$14,243.0017,625View SEC Filing  
7/13/2016Karen L SmithCMOBuy580$143.63$83,305.4013,574View SEC Filing  
6/15/2016Michael Patrick MillerSVPSell100$149.64$14,964.0017,725View SEC Filing  
6/13/2016Karen L SmithCMOBuy557$149.61$83,332.7712,994View SEC Filing  
5/16/2016Heather Ann McsharryDirectorSell697$145.20$101,204.405,396View SEC Filing  
5/16/2016Michael Patrick MillerSVPSell100$145.20$14,520.0017,753View SEC Filing  
4/25/2016Karen J WilsonSVPSell604$160.00$96,640.0018,059View SEC Filing  
4/15/2016Michael Patrick MillerSVPSell100$145.79$14,579.0018,792View SEC Filing  
4/13/2016Karen J WilsonSVPSell5,007$150.00$751,050.0018,663View SEC Filing  
4/12/2016Russell J CoxCOOSell4,000$136.98$547,920.0060,470View SEC Filing  
4/7/2016Karen J WilsonSVPSell2,161$140.90$304,484.9023,670View SEC Filing  
3/15/2016Michael Patrick MillerSVPSell100$129.17$12,917.0018,892View SEC Filing  
3/8/2016Bruce C CozaddCEOSell2,500$126.04$315,100.00302,566View SEC Filing  
2/29/2016Paul TreacySVPSell354$123.48$43,711.9215,102View SEC Filing  
2/23/2016Seamus MulliganDirectorSell27,968$122.71$3,431,953.281,127,831View SEC Filing  
2/16/2016Michael Patrick MillerSVPSell100$115.63$11,563.0013,461View SEC Filing  
2/10/2016Patrick G EnrightDirectorSell10,000$117.92$1,179,200.001,310View SEC Filing  
2/9/2016Bruce C CozaddCEOSell2,500$111.37$278,425.00281,896View SEC Filing  
1/15/2016Michael Patrick MillerSVPSell100$122.66$12,266.0013,561View SEC Filing  
1/12/2016Bruce C CozaddCEOSell2,500$123.81$309,525.00284,396View SEC Filing  
1/5/2016Patrick G EnrightDirectorSell10,000$138.09$1,380,900.001,310View SEC Filing  
12/15/2015Michael Patrick MillerSVPSell100$136.99$13,699.0013,661View SEC Filing  
12/8/2015Bruce C CozaddCEOSell2,500$139.72$349,300.00286,855View SEC Filing  
12/2/2015Patrick G EnrightDirectorSell10,424$146.67$1,528,888.081,310View SEC Filing  
11/23/2015Seamus MulliganDirectorSell27,968$145.86$4,079,412.481,130,547View SEC Filing  
11/10/2015Bruce C CozaddCEOSell2,500$128.53$321,325.00289,355View SEC Filing  
11/10/2015Patrick G EnrightDirectorSell10,000$135.29$1,352,900.001,734View SEC Filing  
10/21/2015Suzanne Sawochka HooperEVPSell2,000$125.00$250,000.0035,855View SEC Filing  
10/13/2015Bruce C CozaddCEOSell2,500$131.50$328,750.00291,855View SEC Filing  
10/5/2015Patrick G EnrightDirectorSell10,000$133.79$1,337,900.001,734View SEC Filing  
9/25/2015Michael Patrick MillerSVPSell100$145.23$14,523.0013,890View SEC Filing  
9/8/2015Bruce C. CozaddCEOSell2,500$163.07$407,675.00294,355View SEC Filing  
9/1/2015Patrick G EnrightDirectorSell10,000$165.99$1,659,900.001,734View SEC Filing  
7/14/2015Bruce C CozaddCEOSell5,000$177.79$888,950.00View SEC Filing  
7/14/2015Suzanne Sawochka HooperEVPSell4,000$177.79$711,160.00View SEC Filing  
7/6/2015Patrick G EnrightDirectorSell10,000$177.11$1,771,100.00View SEC Filing  
6/9/2015Bruce C CozaddCEOSell5,000$173.16$865,800.00View SEC Filing  
6/9/2015Suzanne Sawochka HooperEVPSell4,000$173.16$692,640.00View SEC Filing  
6/2/2015Karen J WilsonSVPSell5,751$179.59$1,032,822.09View SEC Filing  
6/1/2015Karen J WilsonSVPSell5,494$179.57$986,557.58View SEC Filing  
4/14/2015Bruce C CozaddCEOSell5,000$181.45$907,250.00View SEC Filing  
4/14/2015Suzanne Sawochka HooperEVPSell4,000$181.45$725,800.00View SEC Filing  
3/25/2015Seamus MulliganDirectorSell50,000$174.59$8,729,500.00View SEC Filing  
1/5/2015Patrick G EnrightDirectorSell10,000$160.25$1,602,500.00View SEC Filing  
12/26/2014Seamus MulliganDirectorSell50,000$163.40$8,170,000.00View SEC Filing  
12/12/2014Patrick G EnrightDirectorSell2,343$170.98$400,606.14View SEC Filing  
12/9/2014Bruce C CozaddCEOSell5,000$178.79$893,950.00View SEC Filing  
12/9/2014Suzanne Sawochka HooperEVPSell1,852$178.79$331,119.08View SEC Filing  
12/1/2014Patrick G EnrightDirectorSell10,000$172.74$1,727,400.00View SEC Filing  
11/24/2014Jeffrey K TobiasCMOSell4,598$170.12$782,211.76View SEC Filing  
11/7/2014Iain McgillSVPSell7,066$172.03$1,215,563.98View SEC Filing  
10/10/2014Jeffrey K TobiasCMOSell1,000$154.04$154,040.00View SEC Filing  
10/6/2014Patrick G EnrightDirectorSell10,000$160.56$1,605,600.00View SEC Filing  
9/25/2014Seamus MulliganDirectorSell50,000$163.16$8,158,000.00View SEC Filing  
9/24/2014Seamus MulliganDirectorSell35,294$163.70$5,777,627.80View SEC Filing  
9/12/2014Jeffrey K TobiasCMOSell1,000$171.22$171,220.00View SEC Filing  
9/11/2014Karen J WilsonSVPSell3,000$175.00$525,000.00View SEC Filing  
9/11/2014Seamus MulliganDirectorSell50,000$175.00$8,750,000.00View SEC Filing  
9/9/2014Bruce C CozaddCEOSell5,000$170.32$851,600.00View SEC Filing  
9/8/2014Karen J WilsonSVPSell2,500$170.00$425,000.00View SEC Filing  
9/8/2014Suzanne Sawochka HooperEVPSell1,852$168.00$311,136.00View SEC Filing  
8/12/2014Bruce C CozaddCEOSell5,000$133.15$665,750.00View SEC Filing  
8/12/2014Suzanne Sawochka HooperEVPSell1,185$133.15$157,782.75View SEC Filing  
8/11/2014Jeffrey K TobiasCMOSell4,933$135.42$668,026.86View SEC Filing  
7/8/2014Bruce C CozaddCEOSell5,000$155.00$775,000.00View SEC Filing  
7/8/2014Suzanne Sawochka HooperEVPSell1,853$155.00$287,215.00View SEC Filing  
7/7/2014Karen J WilsonSVPSell2,500$165.00$412,500.00View SEC Filing  
6/25/2014Seamus MulliganDirectorSell50,000$149.69$7,484,500.00View SEC Filing  
6/20/2014Russell J CoxCOOSell2,000$155.00$310,000.00View SEC Filing  
6/17/2014Fintan KeeganEVPSell3,750$150.00$562,500.00View SEC Filing  
6/10/2014Bruce C CozaddCEOSell5,000$142.34$711,700.00View SEC Filing  
5/16/2014Jeffrey TobiasCMOSell1,000$128.01$128,010.0047,103View SEC Filing  
5/13/2014Bruce CozaddCEOSell5,000$128.92$644,600.00606,810View SEC Filing  
4/17/2014Rick WinninghamDirectorSell27,500$140.00$3,850,000.0013,587View SEC Filing  
4/14/2014Jeffrey TobiasCMOSell3,000$128.54$385,620.0048,103View SEC Filing  
4/8/2014Bruce CozaddCEOSell5,000$123.18$615,900.00611,810View SEC Filing  
3/10/2014Jeffrey TobiasCMOSell3,000$152.99$458,970.0048,103View SEC Filing  
3/6/2014Fintan KeeganEVPSell4,640$159.90$741,936.0039,272View SEC Filing  
3/4/2014Seamus MulliganDirectorSell550,000$156.25$85,937,500.001,455,555View SEC Filing  
3/3/2014Patrick EnrightDirectorSell559,628$152.39$85,281,710.92View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Jazz Pharmaceuticals (NASDAQ JAZZ) News Headlines

Source:
DateHeadline
Jazz Pharmaceuticals (JAZZ) Scheduled to Post Quarterly Earnings on TuesdayJazz Pharmaceuticals (JAZZ) Scheduled to Post Quarterly Earnings on Tuesday
www.americanbankingnews.com - February 20 at 3:28 AM
Interested In Jazz Pharmaceuticals Public Limited Company (NASDAQ:JAZZ)? Here’s What Its Recent Performance Looks LikeInterested In Jazz Pharmaceuticals Public Limited Company (NASDAQ:JAZZ)? Here’s What Its Recent Performance Looks Like
finance.yahoo.com - February 19 at 5:10 PM
Jazz Pharmaceuticals plc - (JAZZ) Expected to Post Quarterly Sales of $441.40 MillionJazz Pharmaceuticals plc - (JAZZ) Expected to Post Quarterly Sales of $441.40 Million
www.americanbankingnews.com - February 18 at 2:04 AM
Insider Selling: Jazz Pharmaceuticals plc - (JAZZ) EVP Sells 200 Shares of StockInsider Selling: Jazz Pharmaceuticals plc - (JAZZ) EVP Sells 200 Shares of Stock
www.americanbankingnews.com - February 16 at 10:20 PM
 Analysts Expect Jazz Pharmaceuticals plc - (JAZZ) to Announce $2.98 EPS Analysts Expect Jazz Pharmaceuticals plc - (JAZZ) to Announce $2.98 EPS
www.americanbankingnews.com - February 16 at 9:14 PM
Jazz Pharmaceuticals to Report 2017 Fourth Quarter and Full Year Financial Results on February 27, 2018Jazz Pharmaceuticals to Report 2017 Fourth Quarter and Full Year Financial Results on February 27, 2018
finance.yahoo.com - February 14 at 9:42 AM
National Comprehensive Cancer Network® adds Jazz Pharmaceuticals Vyxeos™ (daunorubicin and cytarabine) Liposome for Injection to Clinical Practice Guidelines in OncologyNational Comprehensive Cancer Network® adds Jazz Pharmaceuticals' Vyxeos™ (daunorubicin and cytarabine) Liposome for Injection to Clinical Practice Guidelines in Oncology
finance.yahoo.com - February 9 at 9:49 AM
Jazz Pharmaceuticals plc - (JAZZ) Receives Consensus Rating of "Buy" from AnalystsJazz Pharmaceuticals plc - (JAZZ) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - February 4 at 1:48 AM
Jazz Pharmaceuticals plc - (JAZZ) Expected to Announce Earnings of $2.98 Per ShareJazz Pharmaceuticals plc - (JAZZ) Expected to Announce Earnings of $2.98 Per Share
www.americanbankingnews.com - January 30 at 9:10 PM
Notable ETF Outflow Detected - IHE, PFE, PRGO, JAZZNotable ETF Outflow Detected - IHE, PFE, PRGO, JAZZ
www.nasdaq.com - January 26 at 3:42 PM
Jazz Pharmaceuticals Target of Unusually High Options Trading (JAZZ)Jazz Pharmaceuticals Target of Unusually High Options Trading (JAZZ)
www.americanbankingnews.com - January 25 at 1:52 AM
Stock Review for Biotechs Investors -- Inovio Pharma, Insmed, Intra-Cellular Therapies, and Jazz Pharma - PR Newswire (press release)Stock Review for Biotech's Investors -- Inovio Pharma, Insmed, Intra-Cellular Therapies, and Jazz Pharma - PR Newswire (press release)
www.prnewswire.com - January 22 at 8:08 AM
Financial Survey: Mirati Therapeutics (MRTX) & Jazz Pharmaceuticals (JAZZ)Financial Survey: Mirati Therapeutics (MRTX) & Jazz Pharmaceuticals (JAZZ)
www.americanbankingnews.com - January 21 at 3:25 PM
Jazz Pharmaceuticals plc - (JAZZ) CFO Matthew P. Young Sells 700 SharesJazz Pharmaceuticals plc - (JAZZ) CFO Matthew P. Young Sells 700 Shares
www.americanbankingnews.com - January 18 at 7:58 PM
Michael Patrick Miller Sells 200 Shares of Jazz Pharmaceuticals plc - (JAZZ) StockMichael Patrick Miller Sells 200 Shares of Jazz Pharmaceuticals plc - (JAZZ) Stock
www.americanbankingnews.com - January 17 at 7:34 PM
Jazz Pharmaceuticals plc - (JAZZ) CEO Bruce C. Cozadd Sells 3,000 SharesJazz Pharmaceuticals plc - (JAZZ) CEO Bruce C. Cozadd Sells 3,000 Shares
www.americanbankingnews.com - January 17 at 7:04 PM
Concert Pharmaceuticals Plunges on Patent Petition Setback - NasdaqConcert Pharmaceuticals Plunges on Patent Petition Setback - Nasdaq
www.nasdaq.com - January 16 at 5:25 AM
Concert Pharmaceuticals Plunges on Patent Petition SetbackConcert Pharmaceuticals Plunges on Patent Petition Setback
www.zacks.com - January 15 at 3:16 PM
FY2018 EPS Estimates for Jazz Pharmaceuticals plc - (JAZZ) Lowered by SunTrust BanksFY2018 EPS Estimates for Jazz Pharmaceuticals plc - (JAZZ) Lowered by SunTrust Banks
www.americanbankingnews.com - January 15 at 10:54 AM
$442.90 Million in Sales Expected for Jazz Pharmaceuticals plc - (JAZZ) This Quarter$442.90 Million in Sales Expected for Jazz Pharmaceuticals plc - (JAZZ) This Quarter
www.americanbankingnews.com - January 15 at 2:04 AM
Jazz Pharmaceuticals (JAZZ) Raised to "Hold" at Zacks Investment ResearchJazz Pharmaceuticals (JAZZ) Raised to "Hold" at Zacks Investment Research
www.americanbankingnews.com - January 12 at 9:38 PM
Jazz Pharmaceuticals plc - (JAZZ) Given Average Recommendation of "Buy" by BrokeragesJazz Pharmaceuticals plc - (JAZZ) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - January 10 at 2:10 AM
Analysts Issue Forecasts for Jazz Pharmaceuticals plc -s FY2022 Earnings (JAZZ)Analysts Issue Forecasts for Jazz Pharmaceuticals plc -'s FY2022 Earnings (JAZZ)
www.americanbankingnews.com - January 5 at 8:24 PM
ImmunoGen Starts Phase I Study on Leukemia Candidate IMGN632ImmunoGen Starts Phase I Study on Leukemia Candidate IMGN632
www.zacks.com - January 5 at 3:16 PM
How Jazz’s Erwinaze, Defitelio, and Prialt Performed in 3Q17How Jazz’s Erwinaze, Defitelio, and Prialt Performed in 3Q17
finance.yahoo.com - January 5 at 3:16 PM
How Analysts Rated Jazz Pharmaceuticals in DecemberHow Analysts Rated Jazz Pharmaceuticals in December
finance.yahoo.com - January 4 at 3:15 PM
How Did Jazz Pharmaceuticals Perform in 3Q17?How Did Jazz Pharmaceuticals Perform in 3Q17?
finance.yahoo.com - January 4 at 3:15 PM
How Is Jazz Pharmaceuticals’ Xyrem Positioned after 3Q17?How Is Jazz Pharmaceuticals’ Xyrem Positioned after 3Q17?
finance.yahoo.com - January 4 at 3:15 PM
Jazz Pharmaceuticals to Present at the JP Morgan Healthcare Conference on January 8 - PR Newswire (press release)Jazz Pharmaceuticals to Present at the JP Morgan Healthcare Conference on January 8 - PR Newswire (press release)
www.prnewswire.com - January 4 at 5:20 AM
Jazz Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference on January 8Jazz Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference on January 8
finance.yahoo.com - January 2 at 8:15 PM
Jazz Pharmaceuticals (JAZZ) Coverage Initiated at Leerink SwannJazz Pharmaceuticals (JAZZ) Coverage Initiated at Leerink Swann
www.americanbankingnews.com - January 2 at 5:18 PM
Jazz Pharmaceuticals (JAZZ) Lowered to "Sell" at Zacks Investment ResearchJazz Pharmaceuticals (JAZZ) Lowered to "Sell" at Zacks Investment Research
www.americanbankingnews.com - January 2 at 12:44 PM
Avadel Pharmaceuticals: A Top ROTY Pick For 2018 - Seeking AlphaAvadel Pharmaceuticals: A Top ROTY Pick For 2018 - Seeking Alpha
seekingalpha.com - December 31 at 5:26 AM
$441.37 Million in Sales Expected for Jazz Pharmaceuticals PLC (JAZZ) This Quarter$441.37 Million in Sales Expected for Jazz Pharmaceuticals PLC (JAZZ) This Quarter
www.americanbankingnews.com - December 30 at 2:42 PM
Wells Fargo & Co Reaffirms "Buy" Rating for Jazz Pharmaceuticals (JAZZ)Wells Fargo & Co Reaffirms "Buy" Rating for Jazz Pharmaceuticals (JAZZ)
www.americanbankingnews.com - December 29 at 10:54 PM
ETFs with exposure to Jazz Pharmaceuticals Plc : December 26, 2017ETFs with exposure to Jazz Pharmaceuticals Plc : December 26, 2017
finance.yahoo.com - December 26 at 1:32 PM
Jazz Pharmaceuticals Plc :JAZZ-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017Jazz Pharmaceuticals Plc :JAZZ-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017
finance.yahoo.com - December 25 at 3:50 PM
Jazz Submits NDA to FDA for JZP-110 to Cure Sleep Disorder - NasdaqJazz Submits NDA to FDA for JZP-110 to Cure Sleep Disorder - Nasdaq
www.nasdaq.com - December 23 at 3:19 PM
Jazz Pharmaceuticals (JAZZ) Submits NDA for Solriamfetol for Excessive Sleepiness Associated with Narcolepsy and Obstructive Sleep ApneaJazz Pharmaceuticals (JAZZ) Submits NDA for Solriamfetol for Excessive Sleepiness Associated with Narcolepsy and Obstructive Sleep Apnea
www.streetinsider.com - December 22 at 3:15 PM
Jazz Pharmaceuticals Submits New Drug Application for ... - PR Newswire (press release)Jazz Pharmaceuticals Submits New Drug Application for ... - PR Newswire (press release)
www.prnewswire.com - December 22 at 5:28 AM
BRIEF-Jazz Pharma Submits New Drug Application For Solriamfetol (JZP-110)BRIEF-Jazz Pharma Submits New Drug Application For Solriamfetol (JZP-110)
www.reuters.com - December 21 at 3:15 PM
Jazz Pharmaceuticals Submits New Drug Application for Solriamfetol (JZP-110) for Excessive Sleepiness Associated with Narcolepsy and Obstructive Sleep ApneaJazz Pharmaceuticals Submits New Drug Application for Solriamfetol (JZP-110) for Excessive Sleepiness Associated with Narcolepsy and Obstructive Sleep Apnea
finance.yahoo.com - December 21 at 3:15 PM
United Therapeutics to pay $210 million to resolve U.S. kickback probe - ReutersUnited Therapeutics to pay $210 million to resolve U.S. kickback probe - Reuters
www.reuters.com - December 21 at 5:32 AM
Jazz Pharmaceuticals (JAZZ) Rating Reiterated by B. RileyJazz Pharmaceuticals (JAZZ) Rating Reiterated by B. Riley
www.americanbankingnews.com - December 20 at 4:26 PM
Can Jazz Pharmaceuticals Public Limited Company’s (NASDAQ:JAZZ) ROE Continue To Surpass The Industry Average?Can Jazz Pharmaceuticals Public Limited Company’s (NASDAQ:JAZZ) ROE Continue To Surpass The Industry Average?
finance.yahoo.com - December 20 at 5:22 AM
Jazz Pharmaceuticals Sees Unusually High Options Volume (JAZZ)Jazz Pharmaceuticals Sees Unusually High Options Volume (JAZZ)
www.americanbankingnews.com - December 18 at 3:10 AM
Pennsylvania man admits to trading on tips about drug company - ReutersPennsylvania man admits to trading on tips about drug company - Reuters
www.reuters.com - December 16 at 5:35 AM
Jazz Pharmaceuticals PLC (JAZZ) Receives Consensus Rating of "Buy" from BrokeragesJazz Pharmaceuticals PLC (JAZZ) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - December 16 at 2:28 AM
Pennsylvania man admits to trading on tips about drug companyPennsylvania man admits to trading on tips about drug company
finance.yahoo.com - December 15 at 3:16 PM
Insider Selling: Jazz Pharmaceuticals PLC (JAZZ) EVP Sells 200 Shares of StockInsider Selling: Jazz Pharmaceuticals PLC (JAZZ) EVP Sells 200 Shares of Stock
www.americanbankingnews.com - December 13 at 10:20 PM

SEC Filings

Jazz Pharmaceuticals (NASDAQ:JAZZ) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Jazz Pharmaceuticals (NASDAQ:JAZZ) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Jazz Pharmaceuticals (NASDAQ JAZZ) Stock Chart for Tuesday, February, 20, 2018

Loading chart…

This page was last updated on 2/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.